ASCO 2019 - Chronic Lymphocytic Leukemia

ASCO 2019 - Chronic Lymphocytic Leukemia

Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities

ASCO 2019 - Chronic Lymphocytic Leukemia

Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL

ASCO 2019 - Chronic Lymphocytic Leukemia

Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM

ASCO 2019 - Chronic Lymphocytic Leukemia

Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE

ASCO 2019 - Chronic Lymphocytic Leukemia

Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL

ASCO 2019 - Chronic Lymphocytic Leukemia

Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL

ASCO 2019 - Chronic Lymphocytic Leukemia

Evaluation of the PI3Kδ Inhibitor ME-401 in Patients with Relapsed/Refractory Follicular Lymphoma

ASCO 2019 - Chronic Lymphocytic Leukemia

Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

ASCO 2019 - Chronic Lymphocytic Leukemia

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory CLL

ASCO 2019 - Chronic Lymphocytic Leukemia

Conceptual Model of CLL

1
2

Page 1 of 2
Results 1 - 10 of 18

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.